Ludvik Bernhard, Neuffer Beatrice, Pacini Giovanni
Department of Medicine III, Division of Endocrinology and Metabolism, University of Vienna, Vienna, Austria.
Diabetes Care. 2004 Feb;27(2):436-40. doi: 10.2337/diacare.27.2.436.
To investigate the tolerability, efficacy, and mode of action of Caiapo, an extract of white sweet potatoes, on metabolic control in type 2 diabetic patients.
A total of 61 type 2 diabetic patients treated by diet were given 4 g Caiapo (n = 30; mean age 55.2 +/- 2.1 years; BMI 28.0 +/- 0.4 kg/m(2)) or placebo (n = 31; mean age 55.6 +/- 1.5 years; BMI 27.6 +/- 0.3 kg/m(2)) once daily for 12 weeks. Each subject underwent a 75-g oral glucose tolerance test (OGTT) at baseline and after 1, 2, and 3 months to assess 2-h glucose levels. Additionally, fasting blood glucose, HbA(1c), total cholesterol, and triglyceride levels were measured.
After treatment with Caiapo, HbA(1c) decreased significantly (P < 0.001) from 7.21 +/- 0.15 to 6.68 +/- 0.14%, whereas it remained unchanged (P = 0.23) in subjects given placebo (7.04 +/- 0.17 vs. 7.10 +/- 0.19%). Fasting blood glucose levels decreased (P < 0.001) in the Caiapo group (143.7 +/- 1.9 vs. 128.5 +/- 1.7 mg/dl) and did not change in the placebo group (144.3 +/- 1.9 vs. 138.2 +/- 2.1 mg/dl; P = 0.052). A decrease in body weight was observed in both the placebo group (P = 0.0027) and in the Caiapo group (P < 0.0001), probably due to a better- controlled lifestyle. In the Caiapo group, body weight was related to the improvement in glucose control (r = 0.618; P < 0.0002). Two-hour glucose levels were significantly (P < 0.001) decreased in the Caiapo group (193.3 +/- 10.4 vs. 162.8 +/- 8.2 mg/dl) compared with the placebo group (191.7 +/- 9.2 vs. 181.0 +/- 7.1 mg/dl). Mean cholesterol at the end of the treatment was significantly lower in the Caiapo group (214.6 +/- 11.2 mg/dl) than in the placebo group (248.7 +/- 11.2 mg/dl; P < 0.05). No significant changes in triglyceride levels or blood pressure were observed, and Caiapo was well tolerated without significant adverse effects.
This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes. For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c). Thus, the neutraceutical Caiapo seems to be a useful agent in the treatment of type 2 diabetes.
研究白甘薯提取物Caiapo对2型糖尿病患者代谢控制的耐受性、疗效及作用方式。
共有61例接受饮食治疗的2型糖尿病患者，其中30例（平均年龄55.2±2.1岁；体重指数28.0±0.4kg/m²）每日服用4g Caiapo，31例（平均年龄55.6±1.5岁；体重指数27.6±0.3kg/m²）每日服用安慰剂，为期12周。每位受试者在基线时以及治疗1、2和3个月后进行75g口服葡萄糖耐量试验（OGTT）以评估2小时血糖水平。此外，还测量了空腹血糖、糖化血红蛋白（HbA1c）、总胆固醇和甘油三酯水平。
服用Caiapo治疗后，HbA1c从7.21±0.15%显著降低（P<0.001）至6.68±0.14%，而服用安慰剂的受试者其HbA1c保持不变（P = 0.23）（7.04±0.17% vs. 7.10±0.19%）。Caiapo组空腹血糖水平降低（P<0.001）（143.7±1.9 vs. 128.5±1.7mg/dl），安慰剂组未发生变化（144.3±1.9 vs. 138.2±2.1mg/dl；P = 0.052）。安慰剂组（P = 0.0027）和Caiapo组（P<0.0001）体重均有所下降，这可能归因于生活方式得到更好的控制。在Caiapo组中，体重与血糖控制的改善相关（r = 0.618；P<0.0002）。与安慰剂组（191.7±9.2 vs. 181.0±7.1mg/dl）相比，Caiapo组2小时血糖水平显著降低（P<0.001）（193.3±10.4 vs. 162.8±8.2mg/dl）。治疗结束时，Caiapo组平均胆固醇水平（214.6±11.2mg/dl）显著低于安慰剂组（248.7±11.2mg/dl；P<0.05）。甘油三酯水平和血压未观察到显著变化，且Caiapo耐受性良好，无明显不良反应。
本研究证实了Caiapo对2型糖尿病患者血浆葡萄糖及胆固醇水平具有有益作用。首次通过观察到的HbA1c降低证明了Caiapo对血糖控制的长期疗效。因此，营养保健品Caiapo似乎是治疗2型糖尿病的一种有用药物。
